MARKET

AVRO

AVRO

AVROBIO
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.28
-0.05
-0.44%
Opening 11:28 04/23 EDT
OPEN
11.54
PREV CLOSE
11.33
HIGH
11.64
LOW
11.27
VOLUME
58.20K
TURNOVER
--
52 WEEK HIGH
23.50
52 WEEK LOW
9.94
MARKET CAP
469.50M
P/E (TTM)
-3.4099
1D
5D
1M
3M
1Y
5Y
AVROBIO, Inc. (AVRO) Upgraded to Buy: What Does It Mean for the Stock?
Zacks.com · 2d ago
The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15)
Benzinga · 3d ago
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of...
Business Wire · 04/06 12:00
10-K: AVROBIO, INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations Our management's discussion and...
Edgar Online - (EDG = 10Q, 10K) · 03/18 20:54
Avrobio (AVRO) Gets a Buy Rating from Mizuho Securities
Mizuho Securities analyst Difei Yang maintained a Buy rating on Avrobio (AVRO) today and set a price target of $43.00. The company's shares closed last
SmarterAnalyst · 03/18 15:25
AVROBIO EPS beats by $0.17
AVROBIO (AVRO): Q4 GAAP EPS of -$0.73 beats by $0.17.As of Dec. 31, 2020, AVROBIO had $259.7 million in cash and cash equivalents, as compared to $187.0 million in cash
Seekingalpha · 03/18 11:43
BRIEF-AVROBIO Reports Q4 Net Loss Per Share $0.73
reuters.com · 03/18 11:14
AVROBIO Expects Its Cash, Cash Equivalents as of Dec. 31 to Fund Operating Expenses, Cap Expenditure Requirements Into 1Q 2023
AVROBIO Expects Its Cash, Cash Equivalents as of Dec. 31 to Fund Operating Expenses, Cap Expenditure Requirements Into 1Q 2023
Dow Jones · 03/18 11:06
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AVRO. Analyze the recent business situations of AVROBIO through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AVRO stock price target is 32.86 with a high estimate of 58.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 155
Institutional Holdings: 42.24M
% Owned: 101.48%
Shares Outstanding: 41.62M
TypeInstitutionsShares
Increased
45
6.13M
New
16
1.58M
Decreased
20
2.25M
Sold Out
12
1.23M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.76%
Pharmaceuticals & Medical Research
+0.34%
Key Executives
Chairman/Independent Director
Bruce Booth
President/Chief Executive Officer/Director
Geoff MacKay
President/Chief Executive Officer/Director
Geoffrey MacKay
President/Chief Executive Officer/Director
Geoff Mackay
Chief Financial Officer/Chief Accounting Officer/Treasurer
Erik Ostrowski
Corporate Executive
Birgitte Volck
Chief Technology Officer
Kim Raineri
Other
Deanna Petersen
Secretary
Steven Avruch
Director
Gail Farfel
Independent Director
Ian Clark
Other
Holly May
Independent Director
Phillip Donenberg
Independent Director
Annalisa Jenkins
Independent Director
Christopher Paige
Independent Director
Philip Vickers
No Data
About AVRO
AVROBIO, Inc. is a clinical-stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its product pipeline includes AVR-RD-01, AVR-RD-02, AVR-RD-03 and AVR-RD-04. The Company is developing AVR-RD-01 for the treatment of Fabry disease. AVR-RD-02 is the Company’s gene therapy for Gaucher disease. AVR-RD-03 is being developed for the treatment of Pompe disease. The Company is developing AVR-RD-04 for the treatment of patients with cystinosis.

Webull offers kinds of Avrobio Inc stock information, including NASDAQ:AVRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVRO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVRO stock methods without spending real money on the virtual paper trading platform.